Document:

Exhibit 10.08

                                    AGREEMENT

PARTIES:   QUANTUM           QUANTUM RESEARCH, INC.,
                             an Arizona corporation
                             7975 N. Hayden Road, Suite D333
                             Scottsdale, Arizona 85258

                                       and

           HEALTHLINK:        HEALTHLINK INTERNATIONAL, INC.,
                              a Nevada corporation
                              929 Eastwind Drive, Suite 223
                              Westerville, Ohio 43081

DATE:                                                          December 27, 1999

RECITALS:

A.   Quantum has the exclusive right to purchase specific colostrum/whey
     extracts (the "Extracts") from a third party supplier for use in the
     production of dietary supplements and homeopathic remedies formulated and
     owned by Quantum.

B.   HealthLink is in the business of manufacturing and marketing natural and
     nutritional products, and other products, in the United States and desires
     to market certain Quantum Products, and to manufacture products utilizing
     the Extracts.

C.   Quantum desires to sell its Products and the Extracts to HealthLink and
     grant HealthLink the right to market and manufacture the Products on an
     exclusive basis upon the terms and conditions set forth below.

NOW THEREFORE, for good and valuable consideration the receipt and sufficiency
of which is hereby acknowledged, the parties agree as follows:

SECTION 1 - DEFINITIONS

1.1  Affiliates. Any business entity shall be deemed to be affiliated with
     HealthLink if it, directly or indirectly, controls such entity. An entity
     shall be deemed to be affiliated with another entity, if one of them is the
     subsidiary of the other or both are the subsidiaries of the same entity or
     each of them is ultimately controlled by HealthLink. If two (2) entities
     are affiliated with HealthLink at the same time, they shall be deemed to be
     affiliated with each other.

1.2  Confidential Information: Confidential Information means all information
     that is of a proprietary nature, including without limitations, the
     Specifications and all other technical information, methods, processes,
     techniques, data bases, computer programs, descriptions, drawings,
     documents, sketches, files, records, data, designs, plans, and any other

<PAGE>

     information that concerns any dietary supplements or other products
     formulated and owned by Quantum as well as the Products as defined herein.
     Confidential information also includes as to HealthLink and its affiliates,
     all information of a proprietary nature relating to its or their
     independent associates including without limitation current and historic
     population counts, names, addresses, telephone numbers, and e-mail
     addresses; also current and projected recurring levels; current and
     projected product inventory levels, turnovers and turnover ratios; current
     and projected product sales levels, costs of sales, commissions and
     proposals or plans for commission program changes.

1.3  Governmental Agencies: Governmental Agencies shall mean any agency having
     jurisdiction over the Products in the Territory.

1.4  Payment: All references to payments shall refer to United States dollars.

1.5  Products: Products shall mean those certain Quantum products described in
     Exhibit A attached hereto and any subsequent addenda thereto signed by both
     parties.

1.6  Specifications: Specifications shall mean the specific formulae developed
     by Quantum for the production of its products including the Products which
     are the subject of this Agreement.

1.7  Territory: Territory shall mean the United States of America.

SECTION 2 - GRANT OF LICENSE

2.1  Quantum hereby grants to HealthLink and its Affiliates the right to
     distribute and sell the Products in the Territory on an exclusive basis,
     subject to the terms of this Agreement. Quantum further grants to
     HealthLink the right to manufacture the Products utilizing the Extracts and
     to distribute and sell same, subject to the terms of this Agreement.

SECTION 3 - QUANTUM'S OBLIGATIONS

3.1  Quantum shall supply HealthLink such amounts of the Products or Extracts as
     HealthLink needs, subject to the other terms and conditions contained in
     this Agreement.

3.2  Quantum will provide the technical information relating to the Products and
     their ingredients and such other support reasonably required by HealthLink
     in the context of consumer education and simplification of such technical
     information. Quantum will provide, as reasonably required by HealthLink,
     adequate training to sales support staff regarding the Products.

<PAGE>

3.3  At HealthLink' request, Quantum will provide, in its reasonable discretion
     and as such may relate to the Products, (i) current and subsequent
     scientific, medical and clinical studies, (ii) the right to the use of the
     name, image, likeness, picture sayings, writings and reputation of the
     members of Quantum's medical professionals, and (iii) copies of all press
     releases and other marketing materials used by Quantum.

3.4  To the extent HealthLink undertakes the manufacture of any Products,
     Quantum will provide to HealthLink all necessary technical information
     including raw material specifications, production and testing methods,
     packaging specifications, stability data and technical support to enable
     HealthLink to manufacture the Products.

3.5  Quantum shall not compete directly or indirectly with HealthLink or assist
     any other person or entity to compete with HealthLink in the manufacture,
     sale, or distribution of the Products in the Territory. However, Quantum
     shall not be liable to HealthLink for third parties that, make, advertise,
     sell or distribute the Products without Quantum's consent. HealthLink
     understands that Quantum has developed other products that may be similar
     in nature to the Products and that these products may be present or
     presented in the Territory by others and that this covenant shall not apply
     to such other products.

3.6  Quantum shall provide HealthLink the benefit and description of all
     licenses, certifications and permits issued by any governmental,
     regulatory, or non-public agency or organization with respect to the
     Products, including Licenses, certifications and permits issued by the
     United States Food and Drug Administration or any other authorized agency
     as may be encountered in advancing the sale of the Products. Quantum shall
     provide ongoing assistance to HealthLink to the extent necessary to secure
     the benefits of any such licenses, certifications, and permits.

3.7  Quantum shall not disclose any Confidential Information peculiar to
     HealthLink to any third parties without HealthLink's written consent.

3.8  Quantum warrants that the Products will be manufactured in the United
     States of America to the standards of the nutritional supplement industry,
     and Quantum will monitor the manufacturing processes as it deems necessary
     and appropriate to assure quality and Product contamination avoidance. Such
     monitoring will include, but not be limited to, obtaining appropriate
     Certificate of Analysis for each ingredient in the Products and selecting a
     manufacturer that applies appropriate standards to the manufacturing
     process. Facilities selected for manufacturing will be selected based upon
     criteria that includes licensing, quality control programs, and experience
     in working with the Product materials and reputation.

3.9  Quantum will require each manufacturer to provide a certificate of
     insurance listing Quantum as an additional insured appearing on their
     product liability insurance policy and will, upon request, provide a copy
     of the certificate to HealthLink.

<PAGE>

3.10 Quantum will develop for HealthLink label copy for each product and provide
     assurance that such labeling is in compliance with the current requirements
     of applicable regulatory agencies. Legal fees incurred by Quantum in
     connection with such product labeling will be paid by HealthLink.

3.11 Quantum, upon request from HealthLink, will assist in the development of
     copy for collateral materials related to the Products. Quantum will, upon
     request, review and approve all such collateral materials as directed by
     HealthLink. Collateral materials include, but are not limited to,
     brochures, audiotapes, videotapes, and training manuals. Such review will
     include a legal review to determine that the collateral materials are in
     compliance with the current regulatory requirements of applicable
     regulatory agencies. Legal fees incurred by Quantum in completing this
     review will be paid by HealthLink.

3.12 Quantum, upon request from HealthLink, will assist in addressing issues
     related to its development of an appropriate consumer safety program. Such
     assistance will cover product returns, safety seals, consumer FAQ, lot
     storage, sampling guidelines and such other issues as the parties deem
     appropriate.

3.13 Quantum shall indemnify, defend and hold harmless HealthLink, its
     affiliates, officers and independent sales associates from and against any
     and all claims, demands, losses, costs, expenses, obligations, liabilities,
     damages, recoveries, and deficiencies, including reasonable attorneys' fees
     and costs that HealthLink, its affiliates, officers and independent sales
     associates may incur or suffer, which arise, result from, or relate to
     Quantum's performance, or failure to perform, the warranties, duties and
     responsibilities delineated in paragraphs 3.6, 3.8, 3.10, and 3.11.

SECTION 4 - OBLIGATIONS OF HEALTHLINK

4.1  HealthLink and its affiliates shall not modify, revise, repackage or
     relabel any of the Products prior to sale or distribution of the Products.
     HealthLink, its affiliates and its or their independent associates or
     distributors shall not make any claims or representations regarding the
     nature or composition of the Products or the performance attributes thereof
     which claims or representations are not wholly encompassed within the
     claims made by Quantum in the labeling, use instructions or marketing
     literature or materials prepared or approved in writing for HealthLink, or
     which are otherwise not specifically approved in writing by Quantum prior
     to their use or publication by HealthLink or its affiliates.

4.2  On or before the last day of each month, HealthLink shall provide to
     Quantum reports reflecting all sales of Products during the immediately
     preceding month and all sales on a year-to-date basis through the end of
     the immediately preceding month, the amount of inventory of Products on

<PAGE>

     hand at the end of the immediately preceding month, and the anticipated
     production and ordering schedule for the three-month period following the
     date of each report.

4.3  HealthLink shall indemnify, defend and hold harmless Quantum, its
     affiliates and officers from and against any and all claims, demands,
     losses, costs, expenses, obligations, liabilities, damages, recoveries, and
     deficiencies, including reasonable attorneys' fees and costs that Quantum
     may incur or suffer, which arise, result from, or relate to any violation
     by HealthLink, its affiliates or any of their independent sales associates
     of the restrictions of paragraph 4.1 above.

4.4  HealthLink shall not disclose any Confidential Information peculiar to
     Quantum to any third parties without the written consent of Quantum.

4.5  In the event HealthLink requests that any Quantum personnel or Dr. Jesse
     Stoff travel with respect to the performance of any services required
     hereunder, it shall reimburse Quantum the maximum rates specified in 41
     Code of Federal Regulations Chapter 301 for reimbursement of per diem
     expenses incurred during travel within the continental United States plus
     the actual cost of travel to and from the destination. In the absence of
     per diem guidelines, actual cost shall be reimbursed upon presentation of
     appropriate documentation. Quantum shall furnish HealthLink with such
     records and other documentary evidence as are customarily sufficient to
     satisfy the requirements for substantiation of such expenditures as an
     income tax deduction (or capitalization) pursuant to applicable laws and/or
     regulations. All air travel shall be "First Class".

4.6  HealthLink shall allow upon reasonable request and notice by Quantum, the
     inspection and random sampling by Quantum of the facilities, processes, and
     the Products produced by HealthLink pursuant to this Agreement. Such
     inspections shall not cause any delay of shipments of the Products to
     distributors or purchasers. Quantum shall bear all costs of such
     inspections and testing, including any repackaging costs.

SECTION 5 - FEES

5.1  HealthLink shall pay Quantum pursuant to the fee schedule set forth in
     Exhibit A.

5.2  These prices set forth in Exhibit A may be adjusted by Quantum upon 90 days
     notice to HealthLink. Such adjustments shall be based upon actual increases
     of costs to Quantum for materials and production from its suppliers and
     shall be made to ensure Quantum's margin of profit contemplated under fees
     set forth in Exhibit A.

5.3  HealthLink shall pay Quantum the full price for the initial purchase order
     for the Products upon submission of its purchase order. Thereafter,
     HealthLink shall pay one-half of the price concurrently with the submission
     of its purchase order and the balance upon shipment by Quantum. All
     shipping expenses shall be paid by HealthLink.

<PAGE>

5.4  Payments required by this contract shall be made by wire transfer directly
     to the account of Quantum Research, Inc. Account information will be
     provided by Quantum Research, Inc.

SECTION 6 - SUPPLY

6.1  Upon the terms and subject to the conditions contained herein, Quantum
     shall produce, package, sell and deliver exclusively to HealthLink such
     quantities of the Products as specified in purchase orders submitted by it
     to Quantum from time to time (Purchase Orders) and HealthLink shall
     purchase such Products. Unless otherwise expressly agreed in writing by the
     parties, the terms and conditions of this Agreement shall apply to any
     Purchase Order and shall be deemed to be incorporated into any Purchase
     Order.

6.2  All Products manufactured by Quantum and delivered to HealthLink pursuant
     to this Agreement shall conform in all respects to the formula, packaging
     and labeling specifications set forth in Exhibit A to this Agreement.

6.3  Title to the Products, Extracts, or other components purchased by
     HealthLink under this agreement shall vest in HealthLink when the Product
     has been delivered at the F.O.B. point, which shall be determined by
     Quantum.

6.4  The license granted herein in Section 2 shall remain exclusive so long as
     HealthLink maintains the minimum purchases and pays the corresponding fee
     in each year as set forth in Exhibit A.

6.5  HealthLink will specify in each Purchase Order the quantity of Products to
     be delivered and Quantum shall ship same within sixty (60) days following
     receipt of the Purchase Order. Concurrently upon the execution of this
     Agreement, HealthLink will submit its initial Purchase Order.

6.6  Quantum shall maintain a supply of components necessary to meet the
     requirements of this Agreement for a six month period, either in the form
     of pure Extract or Extract being used in the process of manufacturing to
     meet Purchase Orders currently being processed.

SECTION 7 - LIQUIDATED DAMAGES

7.1  The parties recognize that the calculation of damages in the event either
     party should breach their obligations hereunder regarding the disclosure of
     Confidential Information peculiar to the other party to third parties would
     be difficult to calculate. The parties agree that a minimum assessment of
     damages in the event of such breach by either party shall be $50,000. This
     is not intended to be construed as a penalty but rather the parties' best
     effort to ascertain the fair amount of damages they would sustain in the
     event of such a breach.

<PAGE>

SECTION 8 - INFRINGEMENT

8.1  In the event that HealthLink learns of any infringement or threatened
     infringement or piracy of the Products, or any actual or intended
     passing-off or unfair competition by reason of imitation or otherwise, or
     that any third party alleges, or claims, or intends to allege or claim that
     the Products infringe on its Products in any manner or that the production,
     sale or use of the Products infringes or any other right of a third party,
     HealthLink shall promptly give notice to Quantum together with all such
     information with respect to the infringement as it may from time to time
     obtain. The parties undertake and agree to consult with each other with
     respect to how to respond to each infringement or violation.

8.2  In the event Quantum undertakes the defense or prosecution of any such
     legal proceedings, HealthLink agrees on behalf of, and at Quantum's
     expense, to execute any and all documents and do such acts and things,
     including without limitation, being made a party to such proceedings, as
     may, in the opinion of counsel for Quantum, be necessary of useful to carry
     out such defense or prosecution.

8.3  Notwithstanding the forgoing, if Quantum declines to institute legal
     proceedings, HealthLink may institute legal proceedings at its sole expense
     and Quantum shall fully cooperate with it in connection with such
     proceedings provided, however, Quantum shall always be free, at its own
     cost and expense, to subsequently join in any pending proceedings.

8.4  Legal proceedings as used herein shall include demand letters, negotiation
     and settlement of disputes, as well as the filing of formal legal actions
     with a court of proper jurisdiction. Under no circumstances shall
     HealthLink have the authority to settle or compromise a matter which in any
     way mitigates, lessens of restricts Quantum's ownership in or rights to the
     Products, Extracts, or other components.

SECTION 9 - REPRESENTATIONS AND WARRANTIES OF QUANTUM

9.1  Quantum hereby represents and warrants that:

     9.1.1 It is the holder of sole and exclusive rights, title, property,
          benefit and interest in and to the Products and Extracts for use in
          the Territory;

     9.1.2 It has every legal right to enter into this Agreement and to perform
          the terms and conditions hereof, except as described herein, free of
          any encumbrances whatsoever;

<PAGE>

     9.1.3 It has entered no relationship or agreement, written or oral,
          expressed or implied, which is inconsistent with the provisions of
          this Agreement;

     9.1.4 The sale of the Products by HealthLink will not, to the best of its
          knowledge, constitute an infringement of any patents or other
          proprietary rights owned by any third party or a violation of any
          statutory or regulatory provisions.

9.2  Each of the parties hereto hereby represents to the other that the
     execution and delivery of this Agreement and the performance thereof will
     not contravene or constitute a default under its charter, by-laws or any
     other agreement, instrument or other forms of commitment to which any party
     hereto is also bound.

SECTION 10 - TERM OF AGREEMENT

10.1 This Agreement will run for an initial period of three (3) years commencing
     on the effective date of this Agreement, and is renewable for an additional
     period of five (5) years, subject only to the minimum quantities specified
     in Exhibit A.

10.2 Quantum may suspend or terminate this Agreement as it thinks fit in the
     event of a material breach of its terms which remains uncured for more than
     sixty (60) days from the date HealthLink is notified in writing of such
     breach, or if HealthLink ceases operation or files for relief under the
     insolvency laws of the Territory.

SECTION 11 - GENERAL PROVISIONS

11.1 The Parties hereby acknowledge and agree that each is an independent
     contractor that neither party shall be considered to be the agent,
     representative, master or servant of the other for any purpose whatsoever
     and that neither party has any authority to enter into any contract to
     assume any obligations or to give any warranties or representations on
     behalf of the other party hereto. Nothing in this Agreement shall be
     construed to create a relationship of partners, joint ventures,
     fiduciaries, agency or any other similar relationship between the parties.

11.2 Time shall be of the essence of this Agreement.

11.3 The terms of this Agreement will be kept strictly confidential by both
     parties except to their attorneys, accountants or other professional
     advisors or unless required according to the regulations of any Government
     Agency having competent jurisdiction.

11.4 HealthLink shall have the option to terminate this agreement upon 90 days
     written notice to Quantum Research, Inc.

<PAGE>

11.5 This Agreement has been entered into in the State of Arizona and all
     questions with respect to this Agreement and the rights and liabilities of
     the parties hereto shall be governed by the laws of the State of Arizona.

11.6 If a dispute arises out of or related to this Agreement or the breach
     thereof and if the dispute cannot be settled through negotiation, the
     parties agree first to try in good faith to settle the dispute by mediation
     administered by the American Arbitration Association under its Commercial
     Mediation Rules before resorting to arbitration. Such mediation shall be
     conducted in Phoenix, Arizona within thirty (30) days following receipt by
     the American Arbitration Association of a Request for Mediation or a
     Submission to Dispute Resolution. If the dispute is not resolved through
     mediation it shall be settled by arbitration administered by the American
     Arbitration Association under its Arbitration rules. Such arbitration shall
     be conducted in Phoenix, Arizona by a single arbitrator. No discovery shall
     be conducted prior to such arbitration hearing except that the arbitration
     shall require the parties to exchange a list of witnesses and copies of all
     documents or exhibits either party intends to use at the arbitration.

11.7 This Agreement may not be assigned except to an Affiliate or, with the
     permission of the other party, which permission cannot be unreasonably
     withheld, to the buyer of the party's entire business.

11.8 All notices, requests, demands, and other communication required or
     permitted to be given under this Agreement shall be in writing addressed to
     the other party at the address set forth above, or such other address as
     either party may designate in writing to the other subsequent to the
     execution of this Agreement, and shall be conclusively deemed to have duly
     given (1) when hand delivered to the other party; or (2) when received when
     sent by telex or facsimile at the address and number set forth below
     (provide, however, that notices given by facsimile shall not be effective
     unless either (a) a duplicate copy of such facsimile notice is promptly
     given by depositing same in a United States post office or mailbox with
     first-class postage prepaid and addressed to the parties as set forth
     below, or (b) the receiving party delivers a written confirmation of
     receipt for such notice either by facsimile or any other method permitted
     under this section; or (3) three business days after the same have been
     deposited in a United States post office or mailbox with a first-class or
     certified mail, return receipt requested, postage prepaid; or (4) the next
     business day after same have been deposited with a national overnight
     delivery service reasonably approved by the parties (Federal Express,
     Airborne, United Parcel Service, and DHL WorldWide Express being deemed
     approved by the parties), shipping prepaid, addressed to the parties as set
     forth below with next-business day delivery guaranteed, provided that the
     sending party receives a confirmation of delivery from the delivery service
     provider. Any notice sent by telex of facsimile received after 4 PM at the
     receiving party's office shall be deemed received on the following day.

11.9 No waiver of any provision or consent to any action shall constitute a
     waiver of any other provision or consent to any other action, whether or
     not similar. No waiver or consent shall constitute a continuing waiver or
     consent or commit a party to provide a waiver in the future except to the
     extent specifically set forth in writing.

<PAGE>

11.10 No amendment, modification, or supplement to this Agreement shall be
     binding on any of the parties unless it is in writing and signed by the
     parties in interest at the time of the modification.

11.11 If any term or provision of this Agreement is determined to be illegal,
     unenforceable, or invalid in whole or in part for any reason, such illegal,
     unenforceable, or invalid provisions or part thereof shall be stricken from
     this Agreement, and such provision shall not affect the legality,
     enforceability, or validity of the remainder of this Agreement. If any
     provision or part thereof of this Agreement is stricken in accordance with
     the provisions of this section, then this stricken provision shall be
     replaced, to the extent possible, with a legal, enforceable, and valid
     provision that is as similar in tenor to the stricken provision as legally
     possible.

11.12 The headings of the various sections and paragraphs hereof are for
     convenience of reference only, and shall in no way alter of affect the
     meaning or construction of any of the provisions of this Agreement.

11.13 All exhibits attached to this Agreement are incorporated in and made a
     part of this Agreement.

11.14 Quantum shall have the option to terminate this agreement upon ninety-(90)
     days written notice to HealthLink if it fails to effectively market the
     Products. Failure to market effectively would be evidenced by an
     accumulation of inventory by HealthLink exceeding twelve (12) months sales
     based on the aggregate monthly sales recorded for the preceding
     twelve-month period. HealthLink undertakes to have an inventory reflecting
     the potential for growth, international market factors and reaction time
     considerations. Quantum also retains the right to terminate the agreement
     upon thirty (30) days written notice to HealthLink should it violate any
     laws, or be formally accused of violating any laws by any governmental
     organization. Quantum shall have sole discretion to determine the efficacy
     and impact of such violations for purposes of this termination provision.

11.15 Any obligations of either party under this agreement that by their nature
     would continue beyond termination, cancellation or expiration of this
     agreement shall survive termination, cancellation or expiration of this
     agreement.

11.16 Neither party shall be responsible for any delay or failure in performance
     of any part of this agreement to the extent that such delay or failure is
     caused by failure of subcontract manufacturing facilities, fire, flood,
     explosion, war, strike, embargo, government requirement, civil or military
     authority, act of God, act or omission of carriers, acts or omissions by a
     government authority (de jure or de facto), riots, revolutions, fuel or
     energy shortages, earthquakes, interruptions in electricity, natural gas,
     water or fuel, or shortages of essential materials ("Force Majeure
     Conditions"). If any Force Majeure Condition occurs, the party and the

<PAGE>

     other party affected by the other's delay or inability to perform may elect
     to: 1) terminate this agreement or the affected part, or 2) suspend this
     agreement for the duration of the Force Majeure Condition. Unless written
     notice is given within thirty (30) days after the affected party is
     notified of the Force Majeure Condition, option (2) shall be deemed
     selected.

11.17 In the event of termination, HealthLink reserves the right to sell its
     ongoing operations or its inventory to a third party within a reasonable
     liquidation period in order to deplete its complete inventory. Quantum
     shall have the right of first refusal to purchase the Products at the same
     cost.

     IN WITNESS WHEREOF, the parties hereto have signed this Agreement on the
dates indicated below to become effective on the date first written above.

                                        QUANTUM RESEARCH, INC.,
                                        an Arizona Corporation

                                        By
                                                 David L. Bergsma
                                                 Its President

                                        HEALTHLINK INTERNATIONAL, INC.,
                                        a Nevada corporation

                                        By
                                                 Nicholas G. Venetis
                                                 Its President and CEOExhibit 10.09

     This Agreement is made as of the 29th day of December 1999 by and between
HealthLink International Inc. a Nevada corporation. 929 Eastwind Dr., Suite 225,
Westerville, OH 43081 ("HLI") and Purchase Plus Buyers Group, INC., an Ohio
corporation, 936 Eastwind Dr., Westerville, OH 43081 ("PPBG").

                                    Recitals
                                    --------

     HLI owns the rights to distribute and sell in the United States of America
(the "Territory") certain dietary supplement products more specifically
described in Exhibit A attached hereto and incorporated herein (the "Products").

     PPBG markets consumer products and services through a nationwide
organization of independent sales associates utilizing a network marketing
program and desires to offer the Products for sale through its network of sales
associates.

     HLI is willing to sell the Products to PPBG for resale through its network-
marketing program subject to the terms and conditions of this agreement.

     Therefore in consideration of the forgoing and for other good and valuable
consideration, the parties agree as follows:

     I. Marketing Rights

          A.   HLI herby grants to PPBG the rights to market the Products in the
               Territory subject to the terms and conditions set forth herein.

          B.   The marketing rights granted hereby shall be exclusive as to
               resale of the Products in the network marketing distribution
               channel in the Territory provided PPBG is in compliance with the
               minimum purchase and inventory control requirements of the set
               forth in paragraph III D.

     II. HLI Obligations

          A.   HLI shall supply PPBG such amounts of the products as PPBG needs,
               subject to other terms and conditions set forth herein.

          B.   Products shall be manufactured and packaged according to the
               standards of the nutritional supplement industry in the United
               Sates, shall by licensed, permitted. and certified as necessary

<PAGE>

     Dietary supplement Product Marketing License and Supply Agreement

               for sale within the United States and shall be labeled in
               compliance with the requirements of applicable regulatory
               agencies.

          C.   HLJ shall indemnify, defend and hold harmless PPBG, its
               affiliates. officers and independent sales associates from and
               against any and all claims, demands, losses, costs, expenses,
               obligations, liabilities, damages, recoveries, and deficiencies,
               including reasonable attorney's fees and costs that PPBG, its
               affiliates, officers and independent sales associates may incur
               or suffer, which arise, result from, or relate to HLI's
               performance, or failure to perform, the warranties, duties and
               responsibilities delineated in paragraph II. B., above.

     III. PPBG Obligations

          A.   PPBG shall pay the prices set forth for the Products in Exhibit
               A. Prices shall include cost of manufacture, packaging, labeling,
               and certain promotional services.

          B.   These prices set forth in Exhibit A may be adjusted by HLI upon
               90 days notice to PPBG. Such adjustments shall be based upon
               actual increases of costs passed on to HLI from its suppliers and
               shall be made to ensure HLI's margin of profit contemplated under
               prices set forth in Exhibit A.

          C.   PPBG shall pay RU the full price for the initial purchase order
               for the Products upon submission of its purchase order.
               Thereafter, PPBG shall pay one-half of the price concurrently
               with the submission of its purchase order and the balance upon
               delivery.

          D.   The marketing rights granted herein in Section I shall remain
               exclusive so long as PPBG maintains the minimum purchases and
               pays the corresponding fee in each period as set forth below:

               15,000 Units of each Product depicted on Exhibit A each three (3)
               month period commencing April 1, 2000. This requirement is in
               addition to any purchases made before April 1, 2000 including the
               initial purchase order described in paragraph III E.

               If additional Products are added to Exhibit A by addenda, the
               three month minimum purchase requirements shall be as agreed upon
               and set forth in the addenda and the three (3) month period as to
                                        2

<PAGE>

     Dietary Supplement Product Marketing License and Supply Agreement

               each such product will commence on the date of each addenda or as
               specified in the addenda.

               Purchases in excess of the minimum purchase requirement shall not
               be applied to the requirements of any other three-month period.

               The parties agree minimum quantities may be subject to the
               manufacturer's guidelines. In such case, PPBG will purchase
               minimums as required by the manufacturer.

          E.   PPBG will specify in each Purchase Order the quantity of Products
               to be delivered and HLI shall cause same within sixty (60) days
               following receipt of the Purchases Order. Concurrently upon the
               execution of this Agreement, PPBG will submit its initial
               Purchase Order for the following products:

                                                          Number of Capsules
               Product                 Units                   Per Unit
               -------                 -----                   --------

               Daily                   10,000                     60
               911                     10,000                     30
               Allergy                  5,000                     60
               Antioxidant             10,000                     60

          F.   PPBG and its affiliates shall not modify, revise, repackage or
               relabel any of the products prior to sale or distribution of the
               products. PPBG its' affiliates and its' or their independent
               associates or distributors shall not make any claims or
               representations regarding the nature of composition of the
               products or the performance attributes thereof which claims or
               representations are not wholly encompassed within the claims made
               in the labeling, use instructions or marketing literature or
               materials prepared or approved in writing for PPBG, or which are
               otherwise not specifically approved in writing by HLI's supplier
               prior to their use or publication by PPBG or its' associates.

          G.   On or before the last day of each month, PPBG shall provide to
               HUI reports reflecting all sales of Products during the
               immediately preceding month and all sales on a year-to-date basis

                                        3

<PAGE>

     Dietary Supplement Product Marketing License and Supply Agreement

               through the end of the immediately preceding month, and the
               anticipated productior and ordering schedule for the three-month
               period following the datc of each report.

          H.   PPBG shall indemnify, defend, and hold harmless HUI, its
               affiliates and officers from and against any and all claims,
               demands, losses, costs, expenses, obligations, liabilities,
               damages, recoveries, and deficiencies, including reasonable
               attorney's fees and costs that HLI may incur or suffer, which
               arise, result from, or relate to any violation by PPBG, its'
               affiliates, or any of their independent sales associates of the
               restrictions of paragraph 111. F.

     IV. Term

          The initial term of this agreement shall run for a period of three (3)
          years from the effective date hereof. Thereafter this agreement may be
          renewed at PPBGs option for a renewal term of five (5) years provided
          the minimum quantities provided for in III D shall be increased to
          25,000 Units per month for each product except Allergy which shall be
          increased to 12,500 per month.

     V. Miscellaneous

          A.   Independent Contactor

               The Parties acknowledge and agree that each is an independent
               contractor and that neither party shall be considered to be the
               agent, representative, master or servant of the other for any
               purpose whatsoever and that neither party has any authority to
               enter into any contract to assume any obligations or to give any
               warranties or representations on behalf of the other party
               hereto. Nothing in this Agreement shall be construed to create a
               relationship of partners, joint venturers, fiduciaries, agency or
               any other similar relationship between the parties.

          B.   This agreement may not be assigned except to an Affiliate or,
               with the permission of the other party, which permission cannot
               be unreasonable withheld, to the buyer of the party's entire
               business.

          C.   No amendement, modification, or supplement to this Agreement
               shall be Binding on any of the parties unless it is in writing
               and signed by the parties in interest at the time of the
               modification.

                                        4

<PAGE>

     Dietary Supplement Product Marketing License and Supply Agreement

          D.   This Agreement has been entered into in the State of Ohio and all
               questions with respect to this Agreement and the rights and
               liabilities of the parties hereto shall be governed by the laws
               of the State of Ohio.

     In witness whereof the parties have signed this Agreement to be effective
     on the date first indicated above.

HealthLink International, Inc. (HLI)

By
   ------------------------------------

Its
   ------------------------------------

Purchase Plus Buyers Group, Inc. (PPBG)

By
   -----------------------------------

Its
    ----------------------------------

                                       5

<PAGE>

Exhibit A

Allergy

Quantity per bottle:         60 capsules
Capsule size:                #1 gelatin
Bottle size:                 100cc
Shelf life:                  2 years
Formula:

          Adrenal (whole gland)                          25mg
          Pantothenic acid                               50mg
          Stinging nettle leaf powder                    100mg
          Ai/E                                           25mg
          In a base of arrowroot, silica, magnesium stearate.

Antioxidant (modified 12/7/99)

Quantity per bottle:                  60 White capsules
Capsule size:                         #0 White gelatin
Bottle size:                          100cc
Shelf life:                           2 years
Formula (Two capsules contain):
         CoEnzymeQlO                                            30mg
         Vitamin A                                              2000 IU
         Vitamin E (d alpha tocopheryl)                         150 IU
         Selenium (selenomethionine)                            26mcg
         Zinc                                                   10mg
         Grape Seed Extract                                     30mg
         Bioflavonoid Complex                                   50 mg
         Quercitin                                              100mg
         L-Glutathione                                          50mg
         Bilberry                                               30mg
         Green Tea Extract                                      50mg
         Hesperidin (40% complex)                               100mg
         Taurine                                                50mg
         Lipoic Acid                                            24mg
         L-Carnitine                                            50mg
         Manganese (Amino acid chelate)                         6mg
         Ai/E                                                   4mg
         Rosemary                                               24mg

<PAGE>

Exhibit a

Daily

Quantity per bottle:                  60 capsules
Capsule size:                         #1 gelatin
Bottle size:                          100cc
Shelf life:                           2 years
Formula:
         Vitamin C                    17.0mg
         Vitamin B1                   .8mg
         Vitamin B2                   .5mg
         Vitamin B3                   5.3mg
         Vitamin B6                   1.3mg
         Vitamin B12                  1.7mg
         Pantolhenic Acid             2.7mg
         Biotin                       53.3mg
         Calcium                      66.7mg
         Magnesium                    26.7mg
         Folic Acid                   100.0mg
         Zinc                         .8mg
         Ai/E                         50.0mg
         In a base of Astragalus
         Trace amounts of amino acids from protein hydrolysate.

911

Quantity per bottle:                  30 capsules
Capsule size:                         #1 gelatin
Bottle size:                          75cc
Shelf life:                           2 years
Formula:
         Echinacea                    100mg
         Siberian Ginseng             100mg
         Ai/E                         100mg

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00006-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00006-of-00352.parquet"}]]